MRKR vs PASG Comparison

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.